Consolidated Q2 FY27 revenue rises 30%, but loss widens sharply

Revenue growth above 20%Net loss reportedNegative operating cash flowResults View source PDF Explain this filing

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹274.45

prior close

₹270.65

announcement price

In-mkt

timing

Nifty Microcap 250market+1.1%-0.4% vs market

Healthcare Research Analytics & Technology peers, median of 5sector-0.1%+0.8% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.8 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+1.7

15m

+0.8

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7+1.1-0.4-0.1+0.8

Next day

-2.9pendingpending-0.8-2.2

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated quarter ended 30 September 2026: revenue rose 30.4% to Rs 119.86 lakh from Rs 91.92 lakh, but loss after tax widened to Rs 10,694.21 lakh from Rs 7,730.99 lakh. Standalone quarter loss was Rs 1,638.13 lakh. Consolidated half-year revenue was Rs 476.44 lakh, loss after tax Rs 23,455.24 lakh and cash from operations negative Rs 22,181.28 lakh.

Likely market impact

Higher revenue offers little comfort as the loss widened sharply and cash from operations stayed negative, likely pressuring sentiment.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹1.20 Cr	₹0.92 Cr	+30.4%
Profit after tax	−₹106.9 Cr	−₹77.31 Cr	loss widened

From the company's XBRL filing, not from the text above. Operating profit and EBITDA margin are not shown for banks and lenders, whose other income is their business.